Palisade Bio Secures CAD$1.39 Million for PALI-2108 Development

Funding Boost for PALI-2108 Development

Palisade Bio, Inc. has recently made headlines by announcing a significant financial boost for its development program concerning PALI-2108. The company, known for its innovative approach to treating autoimmune and inflammatory diseases, reported that it received CAD$1.39 million from Canada’s Scientific Research and Experimental Development (SR&ED) Tax Credit Program. This funding is crucial as it will reimburse development costs previously incurred in collaboration with its co-development partner, Giiant Pharma, Inc.

Overview of the PALI-2108 Program

The PALI-2108 project focuses on developing a new therapeutic option for individuals suffering from Ulcerative Colitis (UC). This condition can significantly impact patients' quality of life, making advancements in treatment essential. As Palisade Bio continues to progress, it is optimistic about its ongoing Phase 1a/b study, which will evaluate the safety and efficacy of PALI-2108.

CEO’s Perspective on the Progress

JD Finley, the Chief Executive Officer of Palisade Bio, expressed enthusiasm regarding the non-dilutive funding received. "This funding, which results from our pre-clinical studies conducted under our co-development agreement with Giiant, strengthens our commitment to find effective solutions for patients with UC," he stated. The CEO further highlighted their eagerness to share topline data from the ongoing clinical study, expected by mid-2025.

Insights into Clinical Trials

Palisade Bio is currently engaged in a Phase 1a/b clinical trial, which encompasses both healthy volunteers and a patient cohort with Ulcerative Colitis. This dual approach allows for comprehensive assessment of PALI-2108's pharmacokinetics, safety, and tolerability. The single-center, double-blind, placebo-controlled nature of the study design provides robust data necessary for further stages of development.

Understanding the Therapeutic Approach

Palisade Bio’s focus on targeting autoimmune, inflammatory, and fibrotic diseases reflects its commitment to improve the landscape of therapeutic options. By developing tailored solutions through its robust research programs, the company aims to address unmet medical needs in the field of inflammatory bowel diseases. PALI-2108 is poised to play a pivotal role in this mission.

The Future of Palisade Bio

Looking ahead, Palisade Bio is enthusiastic about the direction of its clinical development and the potential impact of its pipeline therapies. The recent backing from the SR&ED Tax Credit program not only enhances their financial position but also reinforces their strategic partnership with Giiant. This collaboration aims at refining their therapeutic offerings and expediting the development process.

Getting Involved with Palisade Bio

For those interested in following the latest updates from Palisade Bio, additional information about their ongoing projects, including the clinical trial for PALI-2108, can be found on their official website. Stakeholders and interested parties can also access detailed insights, allowing for a better understanding of their development endeavors.

Frequently Asked Questions

What is the significance of the CAD$1.39 million funding?

The CAD$1.39 million funding from the SR&ED program is crucial for reimbursing development costs associated with PALI-2108, bolstering Palisade Bio's financial capabilities.

What is PALI-2108 targeting?

PALI-2108 is focused on treating Ulcerative Colitis, an autoimmune inflammatory condition affecting millions globally.

When will topline data for PALI-2108 be available?

Topline data from the ongoing Phase 1a/b study is expected in the first half of 2025, offering insights into the safety and efficacy of PALI-2108.

Who is Palisade Bio’s co-development partner?

Palisade Bio’s co-development partner for PALI-2108 is Giiant Pharma, Inc., with whom they are collaborating on various research initiatives.

How can I learn more about Palisade Bio?

More information about Palisade Bio and their innovative projects can be accessed through their official website.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.